NASDAQ : IRLA
Quince Therapeutics, Inc. — Key statistics
United States
Last price 31.62 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 32.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 33.23M |
| Enterprise Value | -82.75M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.02M |
| Shares Outstanding | 1.02M |
| Shares Change (YoY) | +704.22% |
| Shares Change (QoQ) | +1,237.27% |
| Owned by Insiders (%) | 11.91% |
| Owned by Institutions (%) | 11.61% |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.52 |
| Quick Ratio | 14.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -153.84% |
| Return on Assets (ROA) | -31.51% |
| Return on Invested Capital (ROIC) | -55.19% |
| Return on Capital Employed (ROCE) | -52.64% |
| Weighted Average Cost of Capital (WACC) | 11.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.43M |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -2.16M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -90.19% |
| 50-Day Moving Average | 31.07 |
| 200-Day Moving Average | 54.46 |
| Relative Strength Index (RSI) | 52.53 |
| Average Volume (20 Days) | 83,957 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 154,736 |
| Short Previous Month | 59,944 |
| Short % of Shares Out | 15.21% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.80M |
| Pretax Income | -94.64M |
| Net Income | -92.48M |
| EBITDA | -60.65M |
| EBIT | -60.80M |
| Earnings Per Share (EPS) | -$51.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 115.98M |
| Total Debt | n/a |
| Net Cash | 115.98M |
| Net Cash Per Share | $114.04 |
| Equity (Book Value) | 108.49M |
| Book Value Per Share | -34.73 |
| Working Capital | 114.91M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -46.92M |
| Capital Expenditures | -78,000 |
| Depreciation & Amortization | 152,000 |
| Net Borrowing | -5.55M |
| Free Cash Flow | -47.00M |
| FCF Per Share | -$46.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -704.22% |
| Shareholder Yield | -704.22% |
| Earnings Yield | -158.57% |
| FCF Yield | -140.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $75.00 |
| Price Target Difference | 129.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |